THIS MESSAGE BOARD IS NO LONGER ACTIVE.
TO SEE OUR ACTIVE MESSAGE BOARDS, PLEASE GO HERE

Message

Posted by AVN's monomice herpes cream are coming on July 11, 2000 at 07:42:56:

Rituxin (from IDPH) was the first FDA approved drug for cancer (in the US) utilizing monoclonal antibodies. This could have important significance to AVN if they developed it using "monomouse" technology. AVN who owns 100% of the patent equally with IDPH has stated that they have a verbal agreement with IDPH to commercialize "monomice" technology. If brought to the market, "monomouse" technology may compete with ABGX's "xenomouse" and MEDX's "humabmouse". Both ABGX and MEDX became high flying stocks this year based on the mouse technology. AVN, which still sells for less than $3 per share, feels that their technology is superior to that of ABGX and MEDX. AVN has stated that they will announce plans to commercialize "monomouse" technology within 30-60 days or sooner. AVN has also recently been approved for the first over the counter herpes cream using n-docosanol. The product will be marketed by SBH upon final labeling approval. In addition, AVN has the exciting IgE technology in the pipeline which may help bring relief someday to millions of allergy sufferers. The possibility of developing IgE and monoclonal antibodies could make a perfect combination. This puts AVN in company with Genentech (DNA) who have similiar technology using humanized antibodies.